Sangamo CEO granted 2.5M stock options

Sangamo Therapeutics reported that its President, CEO and Director, Sandy Macrae, received a grant of stock options covering 2,500,000 shares of common stock.

Rhea-AI Filing Summary

Sangamo Therapeutics reported that its President, CEO and Director, Sandy Macrae, received a grant of stock options covering 2,500,000 shares of common stock. The options have an exercise price of $0.2601 per share and expire on March 31, 2036.

According to the vesting terms, one-quarter of the option shares will vest and become exercisable on the first anniversary of the grant date, with the remaining shares vesting in 24 equal monthly installments after that, subject to Dr. Macrae’s continuous service and the provisions of the company’s 2018 Equity Incentive Plan.

Insights

Equity compensation analyst

CEO receives a large, long-dated option grant that aligns incentives but does not involve cash buying or selling.

The filing shows Sandy Macrae receiving stock options for 2,500,000 shares of Sangamo Therapeutics common stock at an exercise price of $0.2601 per share, expiring on March 31, 2036. This is classified as a grant or award, not an open-market purchase.

The vesting schedule requires one year of service before any options vest, then 24 monthly installments, all subject to continuous service and the 2018 Equity Incentive Plan. This structure is typical for senior executive incentives, encouraging multi‑year retention and alignment with long‑term share price performance.

The grant adds derivative exposure without immediate share issuance; any future dilution would occur only if the options become exercisable and are actually exercised. Future company disclosures may indicate how this grant compares to prior equity awards and overall CEO compensation levels.

Insider Trade Summary

Grant/Award: 2,500,000 shares

Grant/Award 1 txn

Insider Macrae Sandy

Role PRESIDENT, CEO AND DIRECTOR

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	2,500,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 2,500,000 contracts (Direct)

Footnotes (1)

1. F1. One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

Key Figures

Option grant size: 2,500,000 options Exercise price: $0.2601 per share Expiration date: March 31, 2036 +2 more

5 metrics

Option grant size 2,500,000 options Stock Option (Right to Buy) granted to CEO

Exercise price $0.2601 per share Conversion or exercise price of granted options

Expiration date March 31, 2036 Option expiration for CEO grant

Post-transaction derivative holdings 2,500,000 options Total options following transaction

Initial vesting cliff 25% after 1 year One-quarter vests on first anniversary of grant

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, Continuous Service, 2018 EIP, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

Continuous Service financial

"subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP)"

2018 EIP financial

"as defined in the 2018 EIP"

vesting financial

"shares will vest and become exercisable in 24 successive equal monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Sangamo Therapeutics (SGMO) report for Sandy Macrae?

Sangamo Therapeutics reported that CEO Sandy Macrae received a grant of stock options for 2,500,000 shares of common stock. These options are a derivative award, not an open-market share purchase or sale, and form part of his equity-based compensation package.

What is the exercise price and expiration date of Sandy Macrae’s new SGMO stock options?

The granted stock options have an exercise price of $0.2601 per share and expire on March 31, 2036. This means Macrae can choose to buy shares at $0.2601 up until that expiration date, provided the options have vested and remain outstanding.

How do the 2,500,000 SGMO options granted to Sandy Macrae vest over time?

One-quarter of the 2,500,000 option shares will vest on the first anniversary of the grant date. The remaining three-quarters then vest in 24 equal monthly installments, subject to Macrae’s continuous service and the terms of Sangamo’s 2018 Equity Incentive Plan.

Does Sandy Macrae’s Form 4 for SGMO show any stock sales or open-market purchases?

The Form 4 shows only a grant of stock options classified as a derivative acquisition, with transaction code A. There are no open-market stock purchases or sales reported in this filing, and no tax-withholding or gift transactions are listed.

What does the Form 4 indicate about Sandy Macrae’s derivative holdings after this SGMO grant?

Following the reported transaction, the Form 4 shows 2,500,000 stock options tied to Sangamo common stock. These options represent Macrae’s derivative position from this grant, subject to future vesting, possible exercise decisions, and the expiration date in 2036.

Under what plan were Sandy Macrae’s SGMO stock options granted and what conditions apply?

The options were granted under Sangamo’s 2018 Equity Incentive Plan. Vesting depends on Macrae’s continuous service and may be accelerated as provided in that plan, meaning plan rules can modify vesting in certain corporate or employment events.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/03/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Macrae Sandy

(Last) (First) (Middle)

C/O SANGAMO THERAPEUTICS, INC.

501 CANAL BLVD.

(Street)

RICHMOND CALIFORNIA 94084

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
SANGAMO THERAPEUTICS, INC [ SGMO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT, CEO AND DIRECTOR

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.2601	04/01/2026		A		2,500,000		(1)	03/31/2036	Common Stock	2,500,000	$0	2,500,000	D

Explanation of Responses:

1. One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

	/s/ Scott Willoughby, Attorney-in-Fact	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)